Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision-Making, a Review - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Incorporating Immunotherapy in Head and Neck Surgical Procedures: Connecting Tumor Biology with Perioperative Choices, a Comprehensive Review

  • By

  • Nicholas Brian Shannon

  • Bruce Ashford

  • June 22, 2026

Share

  • 1

    The standard treatment for resectable head and neck squamous cell carcinoma has plateaued, with over 50% of patients experiencing recurrence within 3 years.

  • 2

    Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have changed the treatment paradigm for recurrent or metastatic head and neck squamous cell carcinoma.

  • 3

    Neoadjuvant immunotherapy aims to adapt surgical interventions based on real-time biological responses to improve outcomes.

  • 4

    Tumor Mutational Burden is a crucial predictive biomarker for immune checkpoint inhibitor response in head and neck squamous cell carcinoma.

  • 5

    Dynamic monitoring through liquid biopsy techniques offers real-time assessment of tumor dynamics and treatment efficacy.

Original Source(s)

Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision-Making, a Review

  • by Nicholas Brian Shannon, Bruce Ashford

  • June 22, 2026

Related Content

Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling

CAR T Before Surgery Improves Glioblastoma Control in Mice

Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

  • September 7, 2026

  • 3 min